Talk:Omberacetam: Difference between revisions
>Mydriasis Suggested re-categorisation of Omberacetam. |
>Cosb1 →UK Legal Status: new section |
||
| (36 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
'''Omberacetam''' is the nonproprietary name proposed for '''Noopept''' (see p.68, www.who.int/medicines/publications/druginformation/innlists/PL117.pdf?ua=1). | |||
I | Strictly speaking it does not belong to the racetam class of compounds (as it is a peptide). However, given its similarity it is often compared and categorized adjacent to other racetams. | ||
On a purely pragmatic basis, I suggest we consider migrating [[Noopept]] to the racetam section. The INN may supplant the brand name in future but it's more important we set a standard in terms of naming conventions. | |||
Update: PubChem now refers to Noopept as Omberacetam [ https://pubchem.ncbi.nlm.nih.gov/compound/Noopept ] | |||
Please see above regarding INN and re-categorizing Noopept into the racetam family on a pragmatic basis. -- (unsigned) [[User:Mydriasis|Mydriasis]], 14 January - 13 October 2018 | |||
:{{ping|Mydriasis}} Done. I'll rename the article as well to reflect this change. Thanks for keeping us up to date! --[[User:Clarity|Clarity]] ([[User talk:Clarity|talk]]) 20:58, 23 October 2018 (CEST) | |||
:: We still haven't get the drug class changed yet. While omberacetam is not technically a 2-pyrrolidone because the C=O bond just ain't there, it's developed to be an analogue for one, so I think it deserves a double class designation like "[[peptide]]; [[racetam]] analogue". --[[User:Artoria2e5|Artoria2e5]] ([[User talk:Artoria2e5|talk]]) 08:46, 15 September 2022 (UTC) | |||
== UK Legal Status == | |||
Omberacetam is not illegal to produce/supply/import in the United Kingdom. | |||
Legality is of that similar to other countries, where it cannot be sold for human use. | |||
Source: | |||
https://en.wikipedia.org/wiki/N-Phenylacetyl-L-prolylglycine_ethyl_ester | |||
Latest revision as of 23:04, 14 July 2023
Omberacetam is the nonproprietary name proposed for Noopept (see p.68, www.who.int/medicines/publications/druginformation/innlists/PL117.pdf?ua=1). Strictly speaking it does not belong to the racetam class of compounds (as it is a peptide). However, given its similarity it is often compared and categorized adjacent to other racetams.
On a purely pragmatic basis, I suggest we consider migrating Noopept to the racetam section. The INN may supplant the brand name in future but it's more important we set a standard in terms of naming conventions.
Update: PubChem now refers to Noopept as Omberacetam [ https://pubchem.ncbi.nlm.nih.gov/compound/Noopept ] Please see above regarding INN and re-categorizing Noopept into the racetam family on a pragmatic basis. -- (unsigned) Mydriasis, 14 January - 13 October 2018
- @Mydriasis: Done. I'll rename the article as well to reflect this change. Thanks for keeping us up to date! --Clarity (talk) 20:58, 23 October 2018 (CEST)
- We still haven't get the drug class changed yet. While omberacetam is not technically a 2-pyrrolidone because the C=O bond just ain't there, it's developed to be an analogue for one, so I think it deserves a double class designation like "peptide; racetam analogue". --Artoria2e5 (talk) 08:46, 15 September 2022 (UTC)
UK Legal Status
Omberacetam is not illegal to produce/supply/import in the United Kingdom. Legality is of that similar to other countries, where it cannot be sold for human use.
Source: https://en.wikipedia.org/wiki/N-Phenylacetyl-L-prolylglycine_ethyl_ester